Rizatriptan

Drug Profile

Rizatriptan

Alternative Names: L 705126; Maxalt; Maxalt-MLT; MK 0462; MK 462; Rizatriptan benzoate

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Merck & Co
  • Class Antimigraines; Small molecules; Triazoles; Tryptamines
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Migraine
  • No development reported Motion sickness

Most Recent Events

  • 02 Jan 2013 First generic equivalent of orally disintegrating tablet formulation (wafer) available in USA for Migraine
  • 30 Dec 2012 Generic equivalent of tablet formulation available in USA for Migraine
  • 16 Dec 2011 Launched for Migraine (in children and adolescents) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top